Clinical Trial Update: Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating radiation and cetuximab with intratumoral EGFR antisense DNA in locally advanced head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• intratumoral EGFR antisense DNA (EGFR antisense DNA)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Squamous Cell Carcinoma, Head and Neck Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-09-21